10 May 10 Ranbaxy’s US arm to face patent infringement suit
Ranbaxy Pharmaceuticals Inc had applied for marketing approval of a version of Purdue’s painkiller, Oxycodone.
Read more from the original source:
Ranbaxy’s US arm to face patent infringement suit
Tags: for-marketing, had-applied, Oxycodone, pharmaceuticals
10 May 10 Xanodyne Announces Renewed Focus on Pain Management Market
Xanodyne Pharmaceuticals, Inc., an integrated specialty pharmaceutical company, today announced that it has tightly focused the strategic direction for the company on the pain management market. Â The company plans to leverage its core expertise in the prescription pain category by developing a range of products that address both the acute and chronic pain prescription segments as well as the …
Go here to read the rest:
Xanodyne Announces Renewed Focus on Pain Management Market
Tags: april, core-expertise, pharmaceuticals, today-announced
06 May 10 Local Company Helps Combat Drug Abuse
King Pharmaceuticals is working to develop Oxycodone tablets that are harder to crush or dissolve.
Read the original post:
Local Company Helps Combat Drug Abuse
Tags: a-tip-about, agency-criminal, connection-with, Oxycodone, pharmaceuticals
05 May 10 King Pharmaceuticals And Acura Pharmaceuticals Announce Plans To Submit An NDA For Acuro(R) Tablets Without Niacin
King Pharmaceuticals, Inc. (NYSE: KG) and Acura Pharmaceuticals, Inc. (NASDAQ: ACUR) announced that the Companies plan to develop and submit a New Drug Application (NDA) for Acurox® (oxycodone HC1) Tablets (without niacin) intended to relieve moderate to severe pain and introduce limits and impediments to potential abuse via nasal snorting of crushed tablets and intravenous injection of …
See more here:
King Pharmaceuticals And Acura Pharmaceuticals Announce Plans To Submit An NDA For Acuro(R) Tablets Without Niacin
Tags: and-intravenous, companies, pharmaceuticals, potential-abuse, without-niacin
03 May 10 King Pharmaceuticals and Acura Pharmaceuticals Announce Plans to Submit an NDA for Acurox(R) Tablets Without Niacin
BRISTOL, TN and PALATINE, IL–(Marketwire – 05/03/10) – King Pharmaceuticals, Inc. (NYSE: KG – News ) and Acura Pharmaceuticals, Inc. (NASDAQ: ACUR – News ) today announced that the Companies plan to develop and submit a New Drug Application (NDA) for Acurox (oxycodone HC1) Tablets (without niacin) intended to relieve moderate to severe pain and introduce limits and impediments to potential …
Original post:
King Pharmaceuticals and Acura Pharmaceuticals Announce Plans to Submit an NDA for Acurox(R) Tablets Without Niacin
Tags: and-introduce, application, companies, pharmaceuticals, without-niacin
